11th July, 1999 7.30 pm | Keynote Speaker |
- Dr. Robert Weinberg, Whitehead Institute
12th July, 1999 (morning) | Oncogene Signalling |
Chairperson: Ed Sausville, National Cancer Institute
- Herceptin
Bob Cohen, Genentech
- Preclinical and Therapeutic Attributes of EGF Receptor Tyrosine Kinase Inhibitors: The CP-359,774 Paradigm
Mike Morin, Pfizer
- The roles of beta -catenin in epithelial morphogenesis and carcinogenesis
Angela Barth, Satnford University
12th July, 1999 (evening) | Delivery or Tumor Targeting |
Chairperson: Leaf Huang, University of Pittsburgh
- Chemotherapy Targeted to Tumor Vasculature
Wadih Arap, Burnham Institute
- Targeting of tumor endothelial cells with cationic liposomes
Donald McDonald, UCSF
13th July, 1999 (morning) | Angiogenesis |
Chairperson: Laura Shawver, Sugen
- Alpha V integrins as therapeutic targets in anti-angiogenesis
Simon Goodman, Merck Damstedt
- Bay 12-9566, a novel matrix metalloproteinase inhibitor
Rachel Humphrey, Bayer
- The development of selective vs non-selective tyrosine kinase inhibitors as anti-angiogenic therapeutics; preclinical and clinical experiences
Julie Cherrington, Sugen
13th July, 1999 (evening) | Cell Cycle |
Chairperson: Patrick O'Connor, Agouron
- Peptidyl Prolyl Isomerases and Cell cycle regulation
Kun Ping Luo, Harvard
- The Polo-Like Kinase: Implications for cell cycle regulation and Cancer
Doug Ferris, National Cancer Institute
14th July, 1999 (morning) | Lipid Regulated Signaling |
Chairperson: Bob Abraham, Duke University
- Sphingolipids and the eukaryotic stress response: Implications for chemotherapy induced apoptosis
Yusuf Hannun, MUSC
- Activators and Inhbitors of PKB/akt
David Stokoe, UCSF
- PI-3 Kinase regulation of cell growth and transformation
Anke Klippel, Atugen
14th July, 1999 (evening) | Chemoprevention |
Chairperson: Ethan Dmitrovsky, Dartmouth Medical School
- Cox-2 and colon cancer
Ray DuBois, Vanderbilt University Medical Center
- Clinical studies with NSAIDS in colon cancer
Gideon Steinbach, MD Anderson Cancer Center
15th July, 1999 (morning) | Novel Targets |
Chairperson: Paul Workman, Institute for Cancer Research, England
- Translation factors as potential targets for cancer therapy
Nahum Sonenberg, McGill University
- Activation of the p53 response by inhibition of nuclear export
Sonia Lain, University of Dundee
- Differentiation Therapy of Solid Tumors Through PPAR gamma
Bruce Spiegelman, Dana Farber Cancer Institute
15th July, 1999 (evening) | DNA Damage Response Pathways |
Chairperson: Mary Ann Bjornsti, Thomas Jefferson
- Targeting PARP, PARG and interacting partners in DNA damage signalling pathways
Dr. Elaine Jacobson, University of Kentucky
- Small molecule inhibitors of PARP to modulate DNA damage responses
Dr. Roger Griffin, University of Newcastle
|